MarketResearchFuture.com adds a new Report named as “Global Pancreatic Cancer Market, 2018 Market Research Report” to its research database. The report spread across 146 pages with table and figures in it. Pancreatic Cancer Market research report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion accordingly.
Rising rates in tobacco consumption, increasing cigarette smokers are likely to enhance the growth of Pancreatic Cancer Market. Additionally, rising prevalence of cancer, increase in intake of alcohol, growing obesity rates, and growing awareness pertaining to various treatment options available are propelling the market growth at a Global level. The Global Pancreatic Cancer Market is expected to grow at a CAGR of 8.1% during the forecast period 2018-2023.
Get PDF Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/1638
Key Players
Some of key the players in the market are
- Pharmacyte Biotech Inc. (U.S.),
- OncoGenex Pharmaceuticals Inc. (U.S.),
- Oncolytics Biotech (Canada),
- Diffusion Pharmaceuticals (U.S.),
- Polaris Pharmaceuticals, Inc. (U.S.),
- Sun BioPharma, Inc. (U.S.),
- Midatech Pharma PLC (U.K.),
- Eli Lilly and Company (U.S.),
- Celgene Corporation (U.S.),
- F. Hoffmann-La Roche AG (Switzerland),
- Amgen, Inc. (U.S.),
- Novartis International AG (U.S.),
- Clovis Oncology (U.S.), and others.
Celgene Corporation
Founded in 1980, and headquartered at US, Celgene Corporation is a biopharmaceutical company aimed in the detection and development of treatments for various cancers and inflammatory diseases. Celgene Corporation has its presence all over the world. The firm has focused on various inorganic and organic growth strategies to enhance its services and increase its patient base. For instance in the year 2015, Celgene Corporation received approval from European Commission (EC) for ABRAXANE, a nanotechnology therapy for the treatment of metastatic pancreatic cancer. The firm has been focusing on improving lives of patients with pancreatic cancer. For instance in 2015, Celgene Corporation invested 30% of its revenue on research and development to produce advanced technologies to support patients with pancreatic cancer. By this approval and high research and development expenditure, the firm aims to focus on patient needs and increase its customer base.
Novartis AG
Founded in 1895, and headquartered in Switzerland, Novartis AG is engaged in the manufacture and development of a wide range of healthcare products. In 2016, Novartis and Pfizer collaborated to form a study on tumors driven by mutations in a gene called KRAS that causes cancer. Additionally, in 2017 Novartis and Perthera partnered to support clinical trials for lung cancer patients. This collaboration and partnership enables the firm to widen its foothold in various geographies.
Regional Analysis
The Americas dominate the Global Pancreatic Cancer Market owing to well-developed technology, increasing patient with cancer, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global pancreatic cancer market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.
Asia Pacific is the fastest growing pancreatic cancer market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.
On the other hand, in the Middle East and Africa, pancreatic cancer has become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Segmentations
The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.
On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.
On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.
On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.
Do You Have Query? Ask To Our Experts @ https://www.marketresearchfuture.com/enquiry/1638
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312
